At a glance
- Note: These files are not yet 508
- Slides will be added as they become available.
June 21, 2023
Welcome & Introductions
Introduction
Dr. G Lee
Dr. M Wharton
Respiratory Syncytial Virus Vaccines – Adult
Dr. C Kotton
Dr. A Gurtman
Dr. L Friedland
Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model) [34 pages]
Dr. D Hutton
Dr. I Ortega Sanchez
Updated EtR (incl. GRADE) for 2 vaccines (Pfizer & GSK) [88 pages]
Dr. M Melgar
Clinical considerations for 2 vaccines (Pfizer & GSK) [12 pages]
Dr. A Britton
Polio Vaccine
Dr. O Brooks
Recommendations for Adult Polio Vaccination [75 pages]
Dr. S Kidd
Influenza Vaccines
Dr. K Talbot
Dr. L Grohskopf
Proposed Recommendations [16 pages]
Dr. L Grohskopf
June 22, 2023
Welcome & Introductions
Introduction
Dr. G Lee
Dr. M Wharton
Pneumococcal Vaccines
Dr. K Poehling
Economic analysis and public health impact of PCV20 use in children [33 pages]
Dr. C Stoecker
Comparison of cost-effectiveness analyses on PCV20 use in children [44 pages]
Dr. D Ayabina
Summary of WG interpretation on EtR and policy options [77 pages]
Dr. M Kobayashi
Dengue Vaccines
Dr. W Chen
Introduction of policy questions for TAK-003 [8 pages]
Dr. A Hernandez
Dr. G Espana
Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico [30 pages]
Dr. R Kaul
Partial EtR framework for TAK-003 [65 pages]
Dr. J Wong
Chikungunya Vaccine
Dr. B Bell
Value of chikungunya vaccine to U.S. travelers and providers [30 pages]
Ms. N Lindsey
Chikungunya virus infection among laboratory workers [9 pages]
Dr. S Hills
Update on large chikungunya outbreak in Paraguay [12 pages]
Dr. S Hills
Workgroup plans and timelines [4 pages]
Dr. S Hills
Respiratory Syncytial Virus Vaccines – Pediatric/Maternal
Dr. S Long
Economic analysis of RSVpreF in pediatric populations [52 pages]
Dr. D Hutton
EtR Pfizer maternal RSV vaccine [130 pages]
Dr. K Fleming-Dutra
Economic analysis of combined use of nirsevimab and maternal RSVpreF vaccine [57 pages]
Dr. D Hutton
Clinical considerations for RSV maternal vaccine and nirsevimab [11 pages]
Dr. J Jones
June 23, 2023
Welcome & Introductions
Introduction
Dr. G Lee
Mpox Vaccine
Dr. P Sanchez
Dr. F Minhaj
Use of JYNNEOS During Mpox Outbreaks: Clinical guidance [25 pages]
Dr. A Rao
Considerations for Long-term Protection Against Mpox [24 pages]
Dr. A Rao
Meningococcal Vaccines
Dr. K Poehling
Cost effectiveness analysis [39 pages]
Dr. I Ortega-Sanchez
GRADE/EtR; Summary and workgroup considerations [85 pages]
Dr. S Crow
Vaccine Safety
Dr. T Shimabukuro
The childhood immunization schedule and safety: Studies in the Vaccine Safety Datalink [20 pages]
Dr. M Daley
Dr. A Hviid
COVID-19 Vaccines
Dr. M Daley
Updates to COVID-19 epidemiology and vaccine effectiveness [62 pages]
Dr. F Havers, Dr. R Galang, Dr. R Link-Gelles
Infection-induced and hybrid immunity [14 pages]
Dr. J Jones
Summary and work group considerations [21 pages]
Dr. M Wallace